Category: Dry eye disease

Approximately 16 million people in the U.S. have been diagnosed with dry eye disease [1.8.4]. For those seeking affordable treatment, a common question is: **Is there a generic version of Tyrvaya?** As of September 2025, the answer is no [1.2.2].

Over 38 million Americans suffer from dry eye disease, with many experiencing the evaporative form of the condition [1.3.5]. For these individuals, a key question is: **how much do Miebo eye drops cost without insurance?** The price can be substantial, often exceeding $800 per bottle [1.2.1, 1.2.5].

According to the U.S. Food and Drug Administration (FDA) approvals, there is currently no generic version available for the prescription eye drop Perfluorohexyloctane. The brand-name medication, marketed as Miebo, is the only formulation available for this specific drug, used to treat the signs and symptoms of dry eye disease.

On October 15, 2021, the U.S. Food and Drug Administration (FDA) approved Tyrvaya (varenicline solution) nasal spray, marking the first nasal spray treatment for dry eye disease. So, is Tyrvaya nasal spray FDA approved? Yes, and it offers a novel approach for patients who find using eye drops challenging.

Nearly 16 million people in the U.S. are diagnosed with Dry Eye Disease (DED), a condition with several advanced treatment options [1.11.3]. When considering prescription treatments, a common question arises: **Does Tyrvaya work better than Xiidra?** The answer depends on the individual's specific condition and preferences.

In 2023, eye health company Bausch + Lomb acquired Xiidra from Novartis in a deal worth up to $2.5 billion. For patients wondering, “Is Xiidra being discontinued?”, this change in ownership confirms the medication's continued availability and future in the dry eye treatment market.

With Meibomian Gland Dysfunction (MGD) contributing to over 85% of dry eye disease cases, treatments that target tear evaporation are crucial. Answering the question 'How is Miebo different from Restasis?' reveals two fundamentally different approaches to managing this common condition.

According to a clinical review, millions of people suffer from dry eye disease, which can be caused by either insufficient tear production or excessive tear evaporation. For those with persistent symptoms, the question often arises: **can I use Restasis and Miebo at the same time?** While these medications can be used in conjunction, they work differently and require specific timing to be effective.

Clinical studies of Xiidra showed that between 5% and 25% of patients experienced common side effects such as eye irritation, a metallic taste, or reduced visual acuity. Understanding what are the downsides of Xiidra? is crucial for patients considering this prescription eye drop for dry eye disease.

Approximately 20 million people in the United States have been diagnosed with Dry Eye Disease (DED), a condition for which Xiidra is a common treatment [1.8.1]. Many patients, however, wonder: **why is Xiidra so expensive?** This article explores the primary factors contributing to its high price.